Adding a platelet booster to standard treatment for low-risk MDS
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests whether adding a medication that helps the body make more platelets (called rhTPO) to the usual treatment (cyclosporine) can improve platelet counts and reduce bleeding in people with a type of bone marrow disorder called lower-risk MDS. It may help those who have very low platelets and are at risk of bleeding.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with lower-risk myelodysplastic syndromes (MDS), a condition where the bone marrow doesn't make enough healthy blood cells.
- Your platelet count is very low—either 30 or less, or less than 50 if you have had bleeding problems.
- Your liver and kidney function are within acceptable limits (less than twice the normal upper limit).
- You are able to perform daily activities with some help (ECOG score 0 to 2).
- You have not had certain prior treatments or conditions that are excluded, such as a history of blood cancer, stem cell transplant, or use of specific platelet-boosting drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two drugs, romiplostim and rhTPO, to help increase platelet counts after a stem cell transplant in people with MDS or aplastic anemia. The goal is to see which drug works better at reducing the need for platelet transfusions.
This trial tests whether giving a medicine called rhTPO early can help prevent low blood platelets, a common side effect of the chemotherapy used to prepare your body for a stem cell transplant. The goal is to help you recover faster and reduce the need for platelet transfusions.
This trial is testing whether a combination of two drugs, luspatercept and darbepoetin alfa, can help people with lower-risk myelodysplastic syndromes (MDS) who need frequent red blood cell transfusions. The goal is to see if the combination reduces their need for transfusions.
This study tests a new drug called elritercept for people with myelodysplastic syndromes (MDS) who have low blood counts and need regular blood transfusions. The drug aims to boost red blood cell production and reduce or eliminate the need for transfusions, which can improve energy and quality of life.
This trial tests an investigational drug, TAK-226, for people with lower-risk myelodysplastic syndromes (MDS) who have anemia. The study aims to see if the drug can help improve blood counts and reduce the need for red blood cell transfusions.
This trial tests if combining two platelet-raising drugs (TPO and a TPO receptor agent) can help patients with solid tumors who have very low platelets after cancer treatment. It aims to prevent or treat severe platelet drops.
Hear when a new Lower-risk Myelodysplastic Syndromes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.